210 related articles for article (PubMed ID: 19906306)
1. Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes.
Bar-Magen T; Sloan RD; Faltenbacher VH; Donahue DA; Kuhl BD; Oliveira M; Xu H; Wainberg MA
Retrovirology; 2009 Nov; 6():103. PubMed ID: 19906306
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 Group O Resistance Against Integrase Inhibitors.
Depatureaux A; Mesplède T; Quashie P; Oliveira M; Moisi D; Plantier JC; Brenner B; Wainberg MA
J Acquir Immune Defic Syndr; 2015 Sep; 70(1):9-15. PubMed ID: 26017662
[TBL] [Abstract][Full Text] [Related]
3. Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.
Nguyen HL; Ruxrungtham K; Delaugerre C
Intervirology; 2012; 55(4):287-95. PubMed ID: 22456540
[TBL] [Abstract][Full Text] [Related]
4. Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.
Goethals O; Van Ginderen M; Vos A; Cummings MD; Van Der Borght K; Van Wesenbeeck L; Feyaerts M; Verheyen A; Smits V; Van Loock M; Hertogs K; Schols D; Clayton RF
Antiviral Res; 2011 Aug; 91(2):167-76. PubMed ID: 21669228
[TBL] [Abstract][Full Text] [Related]
5. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
[TBL] [Abstract][Full Text] [Related]
6. Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.
Abram ME; Ram RR; Margot NA; Barnes TL; White KL; Callebaut C; Miller MD
PLoS One; 2017; 12(2):e0172206. PubMed ID: 28212411
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants.
Gutiérrez C; Hernández-Novoa B; Pérez-Elías MJ; Moreno AM; Holguín A; Dronda F; Casado JL; Moreno S
HIV Clin Trials; 2013; 14(1):10-6. PubMed ID: 23372110
[TBL] [Abstract][Full Text] [Related]
8. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants.
Marinello J; Marchand C; Mott BT; Bain A; Thomas CJ; Pommier Y
Biochemistry; 2008 Sep; 47(36):9345-54. PubMed ID: 18702518
[TBL] [Abstract][Full Text] [Related]
9. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor.
Bar-Magen T; Sloan RD; Donahue DA; Kuhl BD; Zabeida A; Xu H; Oliveira M; Hazuda DJ; Wainberg MA
J Virol; 2010 Sep; 84(18):9210-6. PubMed ID: 20610719
[TBL] [Abstract][Full Text] [Related]
11. Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes.
Neogi U; Singh K; Aralaguppe SG; Rogers LC; Njenda DT; Sarafianos SG; Hejdeman B; Sönnerborg A
AIDS; 2018 Feb; 32(4):469-476. PubMed ID: 29239896
[TBL] [Abstract][Full Text] [Related]
12. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes.
Hightower KE; Wang R; Deanda F; Johns BA; Weaver K; Shen Y; Tomberlin GH; Carter HL; Broderick T; Sigethy S; Seki T; Kobayashi M; Underwood MR
Antimicrob Agents Chemother; 2011 Oct; 55(10):4552-9. PubMed ID: 21807982
[TBL] [Abstract][Full Text] [Related]
13. Development of a phenotypic susceptibility assay for HIV-1 integrase inhibitors.
Heger E; Theis AA; Remmel K; Walter H; Pironti A; Knops E; Di Cristanziano V; Jensen B; Esser S; Kaiser R; Lübke N
J Virol Methods; 2016 Dec; 238():29-37. PubMed ID: 27737783
[TBL] [Abstract][Full Text] [Related]
14. In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.
Margot NA; Hluhanich RM; Jones GS; Andreatta KN; Tsiang M; McColl DJ; White KL; Miller MD
Antiviral Res; 2012 Feb; 93(2):288-296. PubMed ID: 22197635
[TBL] [Abstract][Full Text] [Related]
15. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
Oliveira M; Ibanescu RI; Anstett K; Mésplède T; Routy JP; Robbins MA; Brenner BG;
Retrovirology; 2018 Aug; 15(1):56. PubMed ID: 30119633
[TBL] [Abstract][Full Text] [Related]
16. In vitro analysis of the susceptibility of HIV-1 subtype A and CRF01_AE integrases to raltegravir.
Bellecave P; Malato L; Calmels C; Reigadas S; Parissi V; Andreola ML; Fleury H
Int J Antimicrob Agents; 2014 Aug; 44(2):168-72. PubMed ID: 24935032
[TBL] [Abstract][Full Text] [Related]
17. Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout.
Osman N; Mesplède T; Oliveira M; Hassounah S; Wainberg MA; Brenner BG
AIDS; 2018 Aug; 32(13):1773-1780. PubMed ID: 29894388
[TBL] [Abstract][Full Text] [Related]
18. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143.
Métifiot M; Vandegraaff N; Maddali K; Naumova A; Zhang X; Rhodes D; Marchand C; Pommier Y
AIDS; 2011 Jun; 25(9):1175-8. PubMed ID: 21505303
[TBL] [Abstract][Full Text] [Related]
19. Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors.
Serrao E; Odde S; Ramkumar K; Neamati N
Retrovirology; 2009 Mar; 6():25. PubMed ID: 19265512
[TBL] [Abstract][Full Text] [Related]
20. Structural Comparison of Diverse HIV-1 Subtypes using Molecular Modelling and Docking Analyses of Integrase Inhibitors.
Isaacs D; Mikasi SG; Obasa AE; Ikomey GM; Shityakov S; Cloete R; Jacobs GB
Viruses; 2020 Aug; 12(9):. PubMed ID: 32858802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
